We use cookies for analytics and ads to improve your experience. You can accept or decline. See our Privacy Policy.
Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Valuation
Financials (FY2024)
Investment Thesis
Pharmed Limited is one of India's oldest pharmaceutical companies with over 78 years of continuous operation since 1946. Its long history in Mumbai's pharmaceutical ecosystem is a significant positive, suggesting established relationships and regulatory approvals. However, the complete absence of a public website, investor disclosures, or financial data makes it impossible to assess whether the company is actively capitalising on its legacy or operating at a diminished scale. At INR 700 per share, any investment in Pharmed requires direct engagement with the company's management for thorough due diligence.
Pros
Cons
Business Segments
Pharmaceutical Manufacturing & Distribution
Manufacturing and marketing of pharmaceutical formulations across women's health, pediatric, orthopaedic/joint, pain, cardio-diabetic, ENT, urogenital, metabolic, and general health therapy areas.
Revenue Model
Pharmed Limited generates revenue through the manufacture and sale of pharmaceutical formulations to distributors, stockists, hospitals, and retail pharmacies across India. As an established legacy pharmaceutical company, it may also generate distribution margin income from third-party pharmaceutical products handled through its distribution network.
Detailed Analysis
Growth Plans
India's growing pharmaceutical market and ageing population driving sustained demand for established pharma brands
Potential value unlock through strategic sale or merger with a larger pharmaceutical group
Revival of export potential if manufacturing upgrades to meet international GMP standards are made
Brand recognition from 78+ years of operations providing a marketing advantage in domestic therapeutic segments
Industry Tailwinds
Recent Developments
Pharmed Limited continues to operate as an unlisted pharmaceutical company in Mumbai. No material corporate announcements, financial results, or strategic developments have been publicly reported. The company maintains its long-standing presence in Indian pharmaceutical manufacturing.
2024-01Comparable Companies
CIPLA · ~₹95,000 Cr
Frequently Asked Questions
About Pharmed Limited
Pharmed Limited is one of India's oldest pharmaceutical companies, incorporated in 1946 — making it a pre-independence era business with over 78 years of operating history. With CIN U24230MH1946PLC005121, the company is registered at Office No. 21, Second Floor, Badheka Chambers, Manohardas Street, Fort, Mumbai — one of Mumbai's historic commercial districts near the original business hub of the city. The company is classified under the manufacture of pharmaceuticals, medicinal chemicals and botanical products (NIC code), reflecting a broad pharmaceutical manufacturing mandate. Operating revenue for FY2024 is in the range of ₹100 Crore to ₹500 Crore, indicating a substantial mid-market pharmaceutical enterprise. Pharmed Limited has demonstrated strong financial performance in FY2024, with EBITDA growing 76.1% over the prior year and book networth increasing 20.79% — exceptional metrics for a company of its vintage. This suggests either a business turnaround, capacity expansion benefits flowing through, or improved pricing in its pharmaceutical product categories. The company's board reflects its establishment-era heritage with directors including Satyanarayan Agarwal, Yogesh Saran Aurora, Roop Krishen Khar, Kashmiri Lal Kapoor, Krishnamurthy Venkataramani, Noshir Burjor Shroff, Krishan Kumar Aurora, Jagadish Chinnappa, and Suneet Aurora. The Aurora family (multiple Aurora directors) appears to be the primary promoter family. Established in 1946, Pharmed Limited represents one of India's earliest pharmaceutical manufacturers — predating the country's own independence. Such companies have deep institutional knowledge, established distribution networks, and often hold valuable proprietary formulations built over decades. The company's last AGM was held on 10 September 2025, confirming active governance. Pharmed Limited's location in Fort, Mumbai — India's traditional pharmaceutical and trading hub — provides access to domestic and export market channels.
Key Milestones
Incorporated December 10, 1946 in Mumbai, Maharashtra (CIN: U24230MH1946PLC005121) — 78+ years old
Common questions about unlisted shares
You buy from and sell to the wisefolio desk — shares route through the desk's demat, money-in before shares-out.
You enquire
· Takes 2 minutesTell us the company and quantity you want. Share your demat details so we can settle directly into your account.
We source & quote
· Typically within 1 business dayOur desk sources the shares and comes back with a firm price and an allocation for the quantity available.
You accept the allocation
· Quote valid for 3 daysReview the price, quantity and total. Accept to lock the allocation. The quote is valid for a short window before it needs re-pricing.
You transfer the funds
· Pay within 2 days of acceptingPay by direct bank transfer to the desk's published account — never to a personal account. We confirm receipt and begin the transfer.
Shares reach your demat
· Usually credited within 2–3 business daysOnce payment is verified, the shares are transferred from the desk's demat into yours, and you receive a transfer confirmation.
A principal desk for unlisted & pre-IPO shares — you transact with us, not a stranger.
You enquire
Takes 2 minutes
We source & quote
Typically within 1 business day
You accept the allocation
Quote valid for 3 days
You transfer the funds
Pay within 2 days of accepting
Shares reach your demat
Usually credited within 2–3 business days
Unlisted shares are illiquid and carry higher risk. Pricing is indicative, not live, and these are private off-market transactions with no exchange settlement guarantee. Read the full risk disclosure.
Be the first to discuss Pharmed Limited — share your research, ask questions, or compare notes with other investors.
India's growing pharmaceutical market and ageing population driving sustained demand for established pharma brands
Potential value unlock through strategic sale or merger with a larger pharmaceutical group
Revival of export potential if manufacturing upgrades to meet international GMP standards are made
Brand recognition from 78+ years of operations providing a marketing advantage in domestic therapeutic segments
Industry Headwinds
Failure to modernise manufacturing to comply with revised Schedule M GMP standards could result in regulatory action
Continued absence of public disclosures reducing investor transparency and market interest
Loss of relevance if product portfolio has not been updated to reflect current therapeutic demand trends
Key promoter or management transition risk in a company with such long operating history
Limited public financial disclosure despite being a mid-large company (₹100-500 Crore revenue)
Source: Company Financial Filings
78-year-old company may have legacy manufacturing facilities requiring modernization
Source: AlphaHub Research
Revenue range of ₹100-500 Crore is broad — precise scale not publicly known
Source: Company Financial Filings
A company incorporated in 1946 may face structural challenges in modernising manufacturing to meet current WHO-GMP, Schedule M, and export quality standards required by large institutional buyers.
No publicly available website, financial statements, or management disclosures limit the ability of investors and stakeholders to conduct independent due diligence.
India's pharmaceutical market has consolidated significantly over seven decades. Legacy manufacturers face intense competition from large organised players with superior scale, technology, and marketing capabilities.
Pharmaceutical manufacturing requires continuous GMP compliance under Schedule M (revised 2023) standards. Older manufacturing facilities may require significant capex to meet updated standards.
Unlisted shares with no formal exchange mechanism make it very difficult for investors to buy or sell at fair market value.
PFIZER · ~₹20,000 Cr
ABBOTINDIA · ~₹40,000 Cr
1,541 employees (Mar 2025); pharmaceutical manufacturing and distribution; revenue +21.22% (FY23)
Authorized ₹90 Lakh; paid-up ₹86.12 Lakh; therapy areas: women's health, pediatric, orthopaedic, cardio-diabetic, ENT, general health

SNS Laboratories
Healthcare
₹10
+0.00%